No Prescription |
 |
 | ||
|
OTRIVIN Natru Vent |
|
| ||
No Prescription » Prescription Drugs 12 » OTRIVIN Natru Vent Otrivine nasal spray contains the active ingredient xylometazoline which is a type of medicine called a decongestant. When this medicine is administered into the nose the xylometazoline works by acting on alpha receptors that are found in the walls of blood vessels in the linings of the nasal passages and sinuses. It causes these blood vessels to contract and narrow thereby decreasing blood flow into the linings of the nose and sinuses. This reduces swelling and the feeling of congestion. It also reduces the production of mucus helping to relieve a blocked nose. The nasal spray helps relieve congestion in a few minutes and the effect of the medicine lasts for up to 10 hours. As the medicine causes the blood vessels in the nose to contract it minimises the amount of medicine that is absorbed into the bloodstream from the nose. This means that the nasal drops have a relatively local effect in the nose and are unlikely to have side effects on other parts of the body. What is it used for? Relieving a blocked nose (nasal congestion) associated with colds flu sinusitis and nasal allergies (allergic rhinitis) such as hayfever. Buy OTRIVIN Natru Vent and other Prescription Drugs 12 products online at Medstore. 875
About OTRIVIN Natru Vent: Product Type: Prescription Drugs 12 OTRIVIN ( Natru-Vent Generic Xylometazoline ) OTRIVIN (Natru-Vent Generic Xylometazoline) Natru-Vent Generic Xylometazoline 0.1% w/v 10ml Spray Natru-Vent Generic Xylometazoline OTRIVIN
View more Prescription Drugs 12 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
